Patents by Inventor Caroline Quillent

Caroline Quillent has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Nucleotide sequences of HIV-1 group (or subgroup) O retroviral antigens
    Patent number: 8236324
    Abstract: An HIV-1 type (or subtype) O retrovirus protein, or a natural or synthetic polypeptide or peptide including at least a part of said protein, which is capable of being recognized by antibodies isolated from a serum resulting from infection by an HIV-1 type O VAU strain or an HIV-1 type (or subtype) O DUR strain.
    Type: Grant
    Filed: November 2, 2006
    Date of Patent: August 7, 2012
    Assignee: Institut Pasteur
    Inventors: Pierre Charneau, François Clavel, Andrew Borman, Caroline Quillent, Denise Guetard, Luc Montagnier, Jacqueline Donjon de Saint-Martin, Jacques Cohen
  • Nucleotide sequences of HIV-1 group (or subgroup) O retroviral antigens
    Publication number: 20080261197
    Abstract: An HIV-1 type (or subtype) O retrovirus protein, or a natural or synthetic polypeptide or peptide including at least a part of said protein, which is capable of being recognised by antibodies isolated from a serum resulting from infection by an HIV-1 type O VAU strain or an HIV-1 type (or subtype) O DUR strain.
    Type: Application
    Filed: November 2, 2006
    Publication date: October 23, 2008
    Inventors: Pierre Charneau, Francois Clavel, Andrew Borman, Caroline Quillent, Denise Guetard, Luc Montagnier, Jacqueline Donjon De Saint-Martin, Jacques H.M. Cohen
  • Nucleotide sequences of HIV-1 type (or subtype) O retrovirus antigens
    Patent number: 7157225
    Abstract: An HIV-1 type (or subtype) O retrovirus protein, or a natural or synthetic polypeptide or peptide including at least a part of said protein, which is capable of being recognised by antibodies isolated from a serum resulting from infection by an HIV-1 type O VAU strain or an HIV-1 type (or subtype) O DUR strain.
    Type: Grant
    Filed: December 27, 2001
    Date of Patent: January 2, 2007
    Assignee: Institut Pasteur
    Inventors: Pierre Charneau, François Clavel, Andrew Borman, Caroline Quillent, Denise Guetard, Luc Montagnier, Jacqueline Donjon De Saint-Martin, Jacques H. M. Cohen
  • Nucleotide sequences of HIV-1 group (or subgroup) O retroviral antigens
    Publication number: 20030049604
    Abstract: An HIV-1 type (or subtype) O retrovirus protein, or a natural or synthetic polypeptide or peptide including at least a part of said protein, which is capable of being recognised by antibodies isolated from a serum resulting from infection by an HIV-1 type O VAU strain or an HIV-1 type (or subtype) O DUR strain.
    Type: Application
    Filed: December 27, 2001
    Publication date: March 13, 2003
    Applicant: Institut Pasteur
    Inventors: Pierre Charneau, Francois Clavel, Andrew Borman, Caroline Quillent, Denise Guetard, Luc Montagnier, Jacqueline Donjon De Saint-Martin, Jacques H.M. Cohen
  • Nucleotide sequences of HIV-1 type (or subtype) O retrovirus antigens
    Patent number: 6399294
    Abstract: An HIV-1 type (or subtype) O retrovirus protein, or a natural or synthetic polypeptide or peptide including at least a part of said protein, which is capable of being recognised by antibodies isolated from a serum resulting from infection by an HIV-1 type O VAU strain or an HIV-1 type (or subtype) O DUR strain.
    Type: Grant
    Filed: July 11, 1997
    Date of Patent: June 4, 2002
    Assignee: Institut Pasteur
    Inventors: Pierre Charneau, François Clavel, Andrew Borman, Caroline Quillent, Denise Guetard, Luc Montagnier, Jacqueline Donjon De Saint-Martin, Jacques Cohen
  • Human immunodeficiency virus co-receptor variants associated with resistance to virus infection
    Patent number: 6153431
    Abstract: The present invention relates to variants of the CCR5 human immunodeficiency virus ("HIV") co-receptor which result in a resistance of CCR5 expressing cells to HIV infection. The detection of such mutations may be used to identify individuals at lower risk for infection relative to the general population who, if infected, may exhibit slower progression to AIDS. Further, the present invention provides for methods of inhibiting HIV infection of a cell expressing the CCR5 receptor, comprising introducing, into the cell, a nucleic acid encoding a CCR5 variant.
    Type: Grant
    Filed: May 28, 1998
    Date of Patent: November 28, 2000
    Inventors: Alberto Beretta, Caroline Quillent, Fernando Arenzana Siesdedos, Josephine Braun